{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:35:44Z","timestamp":1794440144615,"version":"4.9.1"},"reference-count":176,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020278","name":"EU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1470"],"award-info":[{"award-number":["SFB1470"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and is characterized by phenotypical heterogeneity with a high prevalence of multiple, often overlapping cardiometabolic disorders. Comorbidities such as hypertension, obesity, or diabetes are present in many HFpEF patients and are hypothesized to contribute to adverse cardiac remodelling and myocardial fibrosis through a variety of haemodynamic and metabolic impairments, with nearly half of all HFpEF patients exhibiting left ventricular (LV) hypertrophy or concentric remodelling. Myocardial fibrosis and its surrogate changes in LV structure and geometry lead to functional impairments such as increased diastolic stiffness and elevated filling pressures and are associated with reduced exercise tolerance and poor prognosis in patients with HFpEF. Despite recent therapeutic progress, there are currently no evidence-based therapies mechanistically focusing solely on myocardial fibrosis and LV hypertrophy in HFpEF. Recognizing myocardial fibrosis and LV hypertrophy as key features of the heterogeneous HFpEF pathophysiology may contribute to the development of promising targets for future clinical trials. This review elaborates on the pathophysiological role of fibrotic remodelling and LV hypertrophy in HFpEF, outlines contemporary diagnostic standards, and discusses emerging therapeutic strategies, aiming at directly modulating myocardial fibrosis and hypertrophy in HFpEF.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehaf524","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T12:00:36Z","timestamp":1755172836000},"page":"37-53","source":"Crossref","is-referenced-by-count":58,"title":["Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-5865","authenticated-orcid":false,"given":"Alexander","family":"Peikert","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Heart Center Graz, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-9831","authenticated-orcid":false,"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[{"name":"Division of Medicine, National Amyloidosis Centre, University College London, Royal Free Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-9597","authenticated-orcid":false,"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4360-1511","authenticated-orcid":false,"given":"Thomas","family":"Thum","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School , Carl-Neuberg-Str. 1, Hannover 30625 ,","place":["Germany"]},{"name":"Center for Translational Regenerative Medicine, Hannover Medical School , Carl-Neuberg-Str. 1, Hannover 30625 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"2026010418524236200_ehaf524-B1","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","article-title":"Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction","volume":"6","author":"Tsao","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026010418524236200_ehaf524-B2","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1016\/S2468-2667(24)00215-9","article-title":"Contemporary epidemiology of hospitalised heart failure with reduced versus preserved ejection fraction in England: a retrospective, cohort study of whole-population electronic health records","volume":"9","author":"Fletcher","year":"2024","journal-title":"Lancet Public Health"},{"key":"2026010418524236200_ehaf524-B3","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B4","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart failure with preserved ejection fraction in perspective","volume":"124","author":"Pfeffer","year":"2019","journal-title":"Circ Res"},{"key":"2026010418524236200_ehaf524-B5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B7","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/jamacardio.2021.1825","article-title":"Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction","volume":"6","author":"Rush","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026010418524236200_ehaf524-B8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1001\/jamacardio.2017.2511","article-title":"Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baseline disease severity and subsequent outcome","volume":"2","author":"Schelbert","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026010418524236200_ehaf524-B9","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B11","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1093\/ehjci\/jeab154","article-title":"Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging","volume":"23","author":"Smiseth","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026010418524236200_ehaf524-B12","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1161\/CIRCULATIONAHA.110.011031","article-title":"Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction","volume":"124","author":"Zile","year":"2011","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B13","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/j.jacc.2019.09.063","article-title":"Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction","volume":"74","author":"Shah","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.114.001583","article-title":"Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial","volume":"7","author":"Shah","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026010418524236200_ehaf524-B15","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1093\/eurheartj\/ehu204","article-title":"New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes","volume":"35","author":"Senni","year":"2014","journal-title":"Eur Heart J"},{"key":"2026010418524236200_ehaf524-B16","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010418524236200_ehaf524-B18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010418524236200_ehaf524-B19","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jacc.2011.07.022","article-title":"Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry","volume":"58","author":"Gaasch","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026010418524236200_ehaf524-B21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1161\/CIRCHEARTFAILURE.113.000887","article-title":"Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial","volume":"7","author":"Shah","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026010418524236200_ehaf524-B22","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIRCULATIONAHA.106.659763","article-title":"Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota","volume":"115","author":"Lam","year":"2007","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B23","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jchf.2013.01.003","article-title":"Heart failure with preserved ejection fraction in African Americans: the ARIC (Atherosclerosis Risk In Communities) study","volume":"1","author":"Gupta","year":"2013","journal-title":"JACC Heart Fail"},{"key":"2026010418524236200_ehaf524-B24","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.jacc.2003.11.040","article-title":"Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry","volume":"43","author":"Klapholz","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B25","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1161\/CIRCHEARTFAILURE.113.000854","article-title":"Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction","volume":"7","author":"Burke","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026010418524236200_ehaf524-B26","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jacc.2006.10.061","article-title":"Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study","volume":"49","author":"Maurer","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B27","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.jcmg.2015.02.014","article-title":"Ethnic-specific normative reference values for echocardiographic LA and LV size, LV mass, and systolic function: the EchoNoRMAL study","volume":"8","author":"Echocardiographic Normal Ranges Meta-Analysis of the Left Heart Collaboration","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026010418524236200_ehaf524-B28","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1161\/CIRCULATIONAHA.108.824243","article-title":"Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short- and long-term change in the Framingham offspring study","volume":"119","author":"Lieb","year":"2009","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jchf.2014.12.018","article-title":"Older adults, \u201cmalignant\u201d left ventricular hypertrophy, and associated cardiac-specific biomarker phenotypes to identify the differential risk of new-onset reduced versus preserved ejection fraction heart failure: CHS (Cardiovascular Health Study)","volume":"3","author":"Seliger","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2026010418524236200_ehaf524-B30","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jacc.2009.09.065","article-title":"Sex-related differences in myocardial remodeling","volume":"55","author":"Piro","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/ejhf.67","article-title":"Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction","volume":"16","author":"Gori","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026010418524236200_ehaf524-B32","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The transition from hypertension to heart failure: contemporary update","volume":"5","author":"Messerli","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026010418524236200_ehaf524-B33","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jacc.2009.08.046","article-title":"Left ventricular mass and ventricular remodeling among Hispanic subgroups compared with non-Hispanic Blacks and Whites: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"55","author":"Rodriguez","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B34","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.amjcard.2010.10.053","article-title":"Differential effect of elevated blood pressure on left ventricular geometry types in Black and White young adults in a community (from the Bogalusa Heart Study)","volume":"107","author":"Wang","year":"2011","journal-title":"Am J Cardiol"},{"key":"2026010418524236200_ehaf524-B35","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/CIRCIMAGING.113.000633","article-title":"Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction","volume":"6","author":"Mascherbauer","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026010418524236200_ehaf524-B36","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026010418524236200_ehaf524-B37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026010418524236200_ehaf524-B38","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010418524236200_ehaf524-B39","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovi\u0107","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026010418524236200_ehaf524-B40","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","article-title":"From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited","volume":"128","author":"Paulus","year":"2021","journal-title":"Circ Res"},{"key":"2026010418524236200_ehaf524-B41","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jacc.2016.03.610","article-title":"When an increase in central systolic pressure overrides the benefits of heart rate lowering","volume":"68","author":"Messerli","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B42","doi-asserted-by":"publisher","first-page":"341583","DOI":"10.1155\/2015\/341583","article-title":"Relevance of sympathetic nervous system activation in obesity and metabolic syndrome","volume":"2015","author":"Thorp","year":"2015","journal-title":"J Diabetes Res"},{"key":"2026010418524236200_ehaf524-B43","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B44","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1161\/01.CIR.56.4.605","article-title":"Prediction of the normal blood volume. Relation of blood volume to body habitus","volume":"56","author":"Feldschuh","year":"1977","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B45","doi-asserted-by":"publisher","first-page":"H331","DOI":"10.1152\/ajpheart.00274.2020","article-title":"Pressure overload generates a cardiac-specific profile of inflammatory mediators","volume":"319","author":"O'Brien","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026010418524236200_ehaf524-B46","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1161\/CIRCHEARTFAILURE.114.001781","article-title":"HDACs regulate miR-133a expression in pressure overload-induced cardiac fibrosis","volume":"8","author":"Renaud","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026010418524236200_ehaf524-B47","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s44161-022-00032-w","article-title":"Immunometabolic mechanisms of heart failure with preserved ejection fraction","volume":"1","author":"Schiattarella","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"2026010418524236200_ehaf524-B48","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","article-title":"Cardiac fibrosis","volume":"117","author":"Frangogiannis","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2026010418524236200_ehaf524-B49","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B50","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/S0140-6736(14)60107-0","article-title":"Cardiovascular remodelling in coronary artery disease and heart failure","volume":"383","author":"Heusch","year":"2014","journal-title":"Lancet"},{"key":"2026010418524236200_ehaf524-B51","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.matbio.2020.04.002","article-title":"Regulators of cardiac fibroblast cell state","volume":"91\u201392","author":"Bretherton","year":"2020","journal-title":"Matrix Biol"},{"key":"2026010418524236200_ehaf524-B52","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrcardio.2014.125","article-title":"Noncoding RNAs and myocardial fibrosis","volume":"11","author":"Thum","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"2026010418524236200_ehaf524-B53","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1161\/CIRCULATIONAHA.108.826230","article-title":"Microarray identifies extensive downregulation of noncollagen extracellular matrix and profibrotic growth factor genes in chronic isolated mitral regurgitation in the dog","volume":"119","author":"Zheng","year":"2009","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B54","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.117.029858","article-title":"Early detection of subclinical myocardial damage in chronic aortic regurgitation and strategies for timely treatment of asymptomatic patients","volume":"137","author":"Lee","year":"2018","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B55","doi-asserted-by":"publisher","first-page":"H151","DOI":"10.1152\/ajpheart.2000.278.1.H151","article-title":"Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control","volume":"278","author":"Nagatomo","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026010418524236200_ehaf524-B56","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","article-title":"Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review","volume":"73","author":"McHugh","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B57","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jcmg.2009.10.012","article-title":"The impact of obesity on the left ventricle: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"3","author":"Turkbey","year":"2010","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026010418524236200_ehaf524-B58","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2337\/db15-0627","article-title":"Relationship between left ventricular structural and metabolic remodeling in Type 2 diabetes","volume":"65","author":"Levelt","year":"2016","journal-title":"Diabetes"},{"key":"2026010418524236200_ehaf524-B59","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1093\/eurheartj\/ehaf057","article-title":"Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"46","author":"Peikert","year":"2025","journal-title":"Eur Heart J"},{"key":"2026010418524236200_ehaf524-B60","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1152\/physrev.00017.2007","article-title":"Cardiac remodeling in obesity","volume":"88","author":"Abel","year":"2008","journal-title":"Physiol Rev"},{"key":"2026010418524236200_ehaf524-B61","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.yjmcc.2015.12.011","article-title":"Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities","volume":"90","author":"Russo","year":"2016","journal-title":"J Mol Cell Cardiol"},{"key":"2026010418524236200_ehaf524-B62","doi-asserted-by":"publisher","first-page":"26","DOI":"10.12997\/jla.2019.8.1.26","article-title":"Established and emerging mechanisms of diabetic cardiomyopathy","volume":"8","author":"Gollmer","year":"2019","journal-title":"J Lipid Atheroscler"},{"key":"2026010418524236200_ehaf524-B63","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1161\/CIRCULATIONAHA.110.955542","article-title":"Myocardial steatosis and biventricular strain and strain rate imaging in patients with Type 2 diabetes mellitus","volume":"122","author":"Ng","year":"2010","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B64","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/ejhf.1617","article-title":"Myocardial adipose deposition and the development of heart failure with preserved ejection fraction","volume":"22","author":"Wu","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010418524236200_ehaf524-B65","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jacc.2015.06.1313","article-title":"Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications","volume":"66","author":"Dzeshka","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B66","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/j.jacc.2012.07.065","article-title":"Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and systolic dysfunction","volume":"60","author":"Ling","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B67","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.amjcard.2012.12.005","article-title":"Left ventricular fibrosis in atrial fibrillation","volume":"111","author":"Shantsila","year":"2013","journal-title":"Am J Cardiol"},{"key":"2026010418524236200_ehaf524-B68","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","article-title":"Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone","volume":"8","author":"Cohen","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026010418524236200_ehaf524-B69","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.yjmcc.2015.11.005","article-title":"Aging and the cardiac collagen matrix: novel mediators of fibrotic remodelling","volume":"93","author":"Horn","year":"2016","journal-title":"J Mol Cell Cardiol"},{"key":"2026010418524236200_ehaf524-B70","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.yjmcc.2019.01.015","article-title":"Pre-existing fibroblasts of epicardial origin are the primary source of pathological fibrosis in cardiac ischemia and aging","volume":"129","author":"Quijada","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"2026010418524236200_ehaf524-B71","doi-asserted-by":"publisher","first-page":"H61","DOI":"10.1152\/ajpheart.00483.2023","article-title":"Substrate stiffness modulates cardiac fibroblast activation, senescence, and proinflammatory secretory phenotype","volume":"326","author":"Felisbino","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026010418524236200_ehaf524-B72","doi-asserted-by":"publisher","first-page":"H745","DOI":"10.1152\/ajpheart.00237.2018","article-title":"Changes in cardiac resident fibroblast physiology and phenotype in aging","volume":"315","author":"Trial","year":"2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026010418524236200_ehaf524-B73","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.jacc.2008.01.011","article-title":"Aging-related defects are associated with adverse cardiac remodeling in a mouse model of reperfused myocardial infarction","volume":"51","author":"Bujak","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B74","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.bbrc.2014.08.109","article-title":"Ageing related periostin expression increase from cardiac fibroblasts promotes cardiomyocytes senescent","volume":"452","author":"Li","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"2026010418524236200_ehaf524-B75","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/eurheartj\/13.suppl_D.17","article-title":"Morphometric investigation of human myocardium in arterial hypertension and valvular aortic stenosis","volume":"13 Suppl D","author":"Schwartzkopff","year":"1992","journal-title":"Eur Heart J"},{"key":"2026010418524236200_ehaf524-B76","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy: JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B77","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"2026010418524236200_ehaf524-B78","doi-asserted-by":"publisher","first-page":"e003090","DOI":"10.1161\/CIRCHEARTFAILURE.116.003090","article-title":"Histological and histometric characterization of myocardial fibrosis in end-stage hypertrophic cardiomyopathy: a clinical\u2013pathological study of 30 explanted hearts","volume":"9","author":"Galati","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026010418524236200_ehaf524-B79","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B80","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/13506129.2024.2405948","article-title":"Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee","volume":"31","author":"Buxbaum","year":"2024","journal-title":"Amyloid"},{"key":"2026010418524236200_ehaf524-B81","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026010418524236200_ehaf524-B82","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac involvement in Fabry disease: JACC review topic of the week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B83","doi-asserted-by":"publisher","first-page":"e2029","DOI":"10.1002\/mgg3.2029","article-title":"X-chromosomal inactivation patterns in women with Fabry disease","volume":"10","author":"Wagenh\u00e4user","year":"2022","journal-title":"Mol Genet Genomic Med"},{"key":"2026010418524236200_ehaf524-B84","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026010418524236200_ehaf524-B85","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.carpath.2018.11.002","article-title":"Lysosomal storage disorders affecting the heart: a review","volume":"39","author":"Nair","year":"2019","journal-title":"Cardiovasc Pathol"},{"key":"2026010418524236200_ehaf524-B86","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/eurheartj\/ehs135","article-title":"Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction","volume":"33","author":"Ohtani","year":"2012","journal-title":"Eur Heart J"},{"key":"2026010418524236200_ehaf524-B87","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jcmg.2014.04.022","article-title":"CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF","volume":"7","author":"Su","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026010418524236200_ehaf524-B88","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jacc.2020.05.072","article-title":"Effect of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF","volume":"76","author":"Cunningham","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B89","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1161\/CIRCHEARTFAILURE.110.960716","article-title":"Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy","volume":"4","author":"Krum","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026010418524236200_ehaf524-B90","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3109\/07853890.2010.538080","article-title":"Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction","volume":"43","author":"de Boer","year":"2011","journal-title":"Ann Med"},{"key":"2026010418524236200_ehaf524-B91","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/jamacardio.2018.2568","article-title":"Association of natriuretic peptides with cardiovascular prognosis in heart failure with preserved ejection fraction: secondary analysis of the TOPCAT randomized clinical trial","volume":"3","author":"Myhre","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026010418524236200_ehaf524-B92","doi-asserted-by":"publisher","first-page":"e011146","DOI":"10.1161\/CIRCHEARTFAILURE.123.011146","article-title":"Proteomic associations of NT-proBNP (N-terminal pro-B-type natriuretic peptide) in heart failure with preserved ejection fraction","volume":"17","author":"Azzo","year":"2024","journal-title":"Circ Heart Fail"},{"key":"2026010418524236200_ehaf524-B93","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1001\/jamacardio.2022.0680","article-title":"Sex and race differences in N-terminal pro-B-type natriuretic peptide concentration and absolute risk of heart failure in the community","volume":"7","author":"Myhre","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026010418524236200_ehaf524-B94","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.CIR.0000112582.16683.EA","article-title":"Impact of obesity on plasma natriuretic peptide levels","volume":"109","author":"Wang","year":"2004","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B95","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/ehf2.13203","article-title":"Circulating multimarker approach to identify patients with preclinical left ventricular remodelling and\/or diastolic dysfunction","volume":"8","author":"Huttin","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026010418524236200_ehaf524-B96","doi-asserted-by":"publisher","first-page":"e002551","DOI":"10.1161\/CIRCHEARTFAILURE.115.002551","article-title":"Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study","volume":"9","author":"Zile","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026010418524236200_ehaf524-B97","doi-asserted-by":"publisher","first-page":"e007885","DOI":"10.1161\/JAHA.117.007885","article-title":"Predictive value of collagen biomarkers for heart failure with and without preserved ejection fraction: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"7","author":"Duprez","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026010418524236200_ehaf524-B98","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/HYPERTENSIONAHA.112.196113","article-title":"Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase","volume":"60","author":"L\u00f3pez","year":"2012","journal-title":"Hypertension"},{"key":"2026010418524236200_ehaf524-B99","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0002-9149(99)80686-9","article-title":"Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis","volume":"75","author":"Klappacher","year":"1995","journal-title":"Am J Cardiol"},{"key":"2026010418524236200_ehaf524-B100","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/eurjhf\/hfq151","article-title":"The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction","volume":"12","author":"Stahrenberg","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026010418524236200_ehaf524-B101","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jchf.2017.07.013","article-title":"Utility of growth differentiation factor-15, a marker of oxidative stress and inflammation, in chronic heart failure: insights from the HF-ACTION study","volume":"5","author":"Sharma","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026010418524236200_ehaf524-B102","doi-asserted-by":"publisher","first-page":"e0232280","DOI":"10.1371\/journal.pone.0232280","article-title":"Characterizing heart failure with preserved and reduced ejection fraction: an imaging and plasma biomarker approach","volume":"15","author":"Kanagala","year":"2020","journal-title":"PLoS One"},{"key":"2026010418524236200_ehaf524-B103","doi-asserted-by":"publisher","first-page":"e005582","DOI":"10.1161\/CIRCHEARTFAILURE.118.005582","article-title":"ST2 in heart failure","volume":"11","author":"Bay\u00e9s-Genis","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026010418524236200_ehaf524-B104","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","author":"Sharma","year":"2004","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B105","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/ejhf.961","article-title":"Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure","volume":"20","author":"Masson","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026010418524236200_ehaf524-B106","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jacc.2018.01.016","article-title":"Spectrum of restrictive and infiltrative cardiomyopathies: Part 1 of a 2-part series","volume":"71","author":"Pereira","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B107","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12968-017-0424-9","article-title":"Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in heart failure with preserved ejection fraction\u2014implications for clinical trials","volume":"20","author":"Kanagala","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026010418524236200_ehaf524-B108","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026010418524236200_ehaf524-B109","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","article-title":"Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach","volume":"56","author":"Kramer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B110","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1161\/CIRCULATIONAHA.105.571653","article-title":"Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study","volume":"112","author":"Izawa","year":"2005","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B111","doi-asserted-by":"publisher","first-page":"e012272","DOI":"10.1161\/JAHA.119.012272","article-title":"Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis","volume":"8","author":"Wang","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026010418524236200_ehaf524-B112","doi-asserted-by":"publisher","first-page":"e002137","DOI":"10.1161\/JAHA.115.002137","article-title":"Effect of mineralocorticoid receptor antagonists on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction: a meta-analysis and systematic review","volume":"4","author":"Pandey","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2026010418524236200_ehaf524-B113","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/ejhf.2726","article-title":"Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials","volume":"25","author":"Ferreira","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026010418524236200_ehaf524-B114","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"2026010418524236200_ehaf524-B115","doi-asserted-by":"publisher","first-page":"e032971","DOI":"10.1161\/JAHA.123.032971","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone improves diastolic dysfunction in preclinical nondiabetic chronic kidney disease","volume":"13","author":"Lima Posada","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026010418524236200_ehaf524-B116","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026010418524236200_ehaf524-B117","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","article-title":"The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study","volume":"38","author":"Schmieder","year":"2017","journal-title":"Eur Heart J"},{"key":"2026010418524236200_ehaf524-B118","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1161\/01.CIR.102.12.1388","article-title":"Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease","volume":"102","author":"Brilla","year":"2000","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B119","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1161\/01.CIR.0000017264.66561.3D","article-title":"Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients","volume":"105","author":"D\u00edez","year":"2002","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B120","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1161\/HYPERTENSIONAHA.109.138529","article-title":"Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction","volume":"55","author":"Solomon","year":"2010","journal-title":"Hypertension"},{"key":"2026010418524236200_ehaf524-B121","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10741-019-09855-5","article-title":"The renin\u2013angiotensin\u2013aldosterone system: a crossroad from arterial hypertension to heart failure","volume":"25","author":"Pugliese","year":"2020","journal-title":"Heart Fail Rev"},{"key":"2026010418524236200_ehaf524-B122","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1001\/jama.1996.03530430051039","article-title":"Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies","volume":"275","author":"Schmieder","year":"1996","journal-title":"JAMA"},{"key":"2026010418524236200_ehaf524-B123","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B124","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/eurheartj\/ehs299","article-title":"Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency","volume":"34","author":"Lam","year":"2013","journal-title":"Eur Heart J"},{"key":"2026010418524236200_ehaf524-B125","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026010418524236200_ehaf524-B126","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010418524236200_ehaf524-B127","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with Type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B128","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cjca.2019.08.033","article-title":"Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results","volume":"36","author":"Kang","year":"2020","journal-title":"Can J Cardiol"},{"key":"2026010418524236200_ehaf524-B129","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1093\/eurheartj\/ehae472","article-title":"Single-nucleus RNA sequencing identifies cell-type-specific effects of sodium-glucose co-transporter 2 inhibitors in human myocardial slices","volume":"45","author":"Schmidt","year":"2024","journal-title":"Eur Heart J"},{"key":"2026010418524236200_ehaf524-B130","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2024","journal-title":"N Engl J Med"},{"key":"2026010418524236200_ehaf524-B131","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","volume":"85","author":"Kramer","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B132","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12933-024-02203-4","article-title":"Evidence that tirzepatide protects against diabetes-related cardiac damages","volume":"23","author":"Taktaz","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026010418524236200_ehaf524-B133","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/oby.22038","article-title":"Bariatric surgery-induced cardiac and lipidomic changes in obesity-related heart failure with preserved ejection fraction","volume":"26","author":"Mikhalkova","year":"2018","journal-title":"Obesity (Silver Spring)"},{"key":"2026010418524236200_ehaf524-B134","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure","volume":"84","author":"Solomon","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B135","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1016\/j.jacc.2014.03.034","article-title":"Implications of coronary artery disease in heart failure with preserved ejection fraction","volume":"63","author":"Hwang","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B136","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jcmg.2017.04.012","article-title":"LV mass independently predicts mortality and need for future revascularization in patients undergoing diagnostic coronary angiography","volume":"11","author":"Abdi-Ali","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026010418524236200_ehaf524-B137","doi-asserted-by":"publisher","first-page":"e006580","DOI":"10.1161\/CIRCIMAGING.117.006580","article-title":"Postoperative reverse remodeling and symptomatic improvement in normal-flow low-gradient aortic stenosis after aortic valve replacement","volume":"10","author":"Carter-Storch","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026010418524236200_ehaf524-B138","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41581-022-00576-x","article-title":"Cardiac metabolic remodelling in chronic kidney disease","volume":"18","author":"Patel","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2026010418524236200_ehaf524-B139","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B140","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1093\/eurheartj\/ehu093","article-title":"Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial","volume":"35","author":"Mahfoud","year":"2014","journal-title":"Eur Heart J"},{"key":"2026010418524236200_ehaf524-B141","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jacc.2011.11.034","article-title":"Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension","volume":"59","author":"Brandt","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B142","doi-asserted-by":"publisher","first-page":"e007421","DOI":"10.1161\/CIRCHEARTFAILURE.120.007421","article-title":"Renal sympathetic denervation in patients with heart failure with preserved ejection fraction","volume":"14","author":"Kresoja","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026010418524236200_ehaf524-B143","doi-asserted-by":"publisher","first-page":"1408547","DOI":"10.3389\/fcvm.2024.1408547","article-title":"Left ventricular structure and function following renal sympathetic denervation in patients with HFpEF: an echocardiographic 9-year long-term follow-up","volume":"11","author":"Vogt","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"2026010418524236200_ehaf524-B144","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.jacc.2013.10.073","article-title":"Improvements in left ventricular hypertrophy and diastolic function following renal denervation: effects beyond blood pressure and heart rate reduction","volume":"63","author":"Schirmer","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B145","doi-asserted-by":"publisher","first-page":"e032646","DOI":"10.1161\/JAHA.123.032646","article-title":"Early renal denervation attenuates cardiac dysfunction in heart failure with preserved ejection fraction","volume":"13","author":"Doiron","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026010418524236200_ehaf524-B146","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.jacc.2010.11.048","article-title":"Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system","volume":"57","author":"Bisognano","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B147","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1002\/ehf2.14940","article-title":"Effects of baroreflex activation therapy on cardiac function and morphology","volume":"11","author":"Sch\u00e4fer","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026010418524236200_ehaf524-B148","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41591-021-01452-0","article-title":"Pirfenidone in heart failure with preserved ejection fraction: a randomized Phase 2 trial","volume":"27","author":"Lewis","year":"2021","journal-title":"Nat Med"},{"key":"2026010418524236200_ehaf524-B149","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/ejhf.3139","article-title":"Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: rationale and design of the HF-REVERT trial","volume":"26","author":"Bauersachs","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026010418524236200_ehaf524-B150","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","article-title":"Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study","volume":"42","author":"T\u00e4ubel","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010418524236200_ehaf524-B151","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41467-020-14349-2","article-title":"Preclinical development of a miR-132 inhibitor for heart failure treatment","volume":"11","author":"Foinquinos","year":"2020","journal-title":"Nat Commun"},{"key":"2026010418524236200_ehaf524-B152","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1093\/eurheartj\/ehae102","article-title":"Inhibition of miR-21: cardioprotective effects in human failing myocardium ex vivo","volume":"45","author":"Abbas","year":"2024","journal-title":"Eur Heart J"},{"key":"2026010418524236200_ehaf524-B153","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.jacc.2020.02.041","article-title":"AntimiR-21 prevents myocardial dysfunction in a pig model of ischemia\/reperfusion injury","volume":"75","author":"Hinkel","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010418524236200_ehaf524-B154","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/nature07511","article-title":"MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts","volume":"456","author":"Thum","year":"2008","journal-title":"Nature"},{"key":"2026010418524236200_ehaf524-B155","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"2026010418524236200_ehaf524-B156","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"2026010418524236200_ehaf524-B157","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1161\/HYPERTENSIONAHA.116.07084","article-title":"Increasing regulatory T cells with interleukin-2 and interleukin-2 antibody complexes attenuates lung inflammation and heart failure progression","volume":"68","author":"Wang","year":"2016","journal-title":"Hypertension"},{"key":"2026010418524236200_ehaf524-B158","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1161\/CIRCULATIONAHA.108.832782","article-title":"Regulatory T cells ameliorate angiotensin II-induced cardiac damage","volume":"119","author":"Kvakan","year":"2009","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B159","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jacbts.2017.12.006","article-title":"CCR2+ monocyte-derived infiltrating macrophages are required for adverse cardiac remodeling during pressure overload","volume":"3","author":"Patel","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"2026010418524236200_ehaf524-B160","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00395-019-0719-0","article-title":"Blocking the IL-1\u03b2 signalling pathway prevents chronic viral myocarditis and cardiac remodeling","volume":"114","author":"Kraft","year":"2019","journal-title":"Basic Res Cardiol"},{"key":"2026010418524236200_ehaf524-B161","doi-asserted-by":"publisher","first-page":"e125074","DOI":"10.1172\/jci.insight.125074","article-title":"Fibroblast-specific deletion of interleukin-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarction","volume":"5","author":"Bageghni","year":"2019","journal-title":"JCI Insight"},{"key":"2026010418524236200_ehaf524-B162","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1161\/CIRCULATIONAHA.120.050682","article-title":"MicroRNA-21-dependent macrophage-to-fibroblast signaling determines the cardiac response to pressure overload","volume":"143","author":"Ramanujam","year":"2021","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B163","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.yjmcc.2018.02.016","article-title":"Pharmacologic inhibition of the enzymatic effects of tissue transglutaminase reduces cardiac fibrosis and attenuates cardiomyocyte hypertrophy following pressure overload","volume":"117","author":"Shinde","year":"2018","journal-title":"J Mol Cell Cardiol"},{"key":"2026010418524236200_ehaf524-B164","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1161\/CIRCULATIONAHA.106.625467","article-title":"Suppression of Class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy","volume":"113","author":"Kong","year":"2006","journal-title":"Circulation"},{"key":"2026010418524236200_ehaf524-B165","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1080\/15592294.2015.1024406","article-title":"HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes","volume":"10","author":"Ooi","year":"2015","journal-title":"Epigenetics"},{"key":"2026010418524236200_ehaf524-B166","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1161\/01.RES.0000197782.21444.8f","article-title":"Control of cardiac growth by histone acetylation\/deacetylation","volume":"98","author":"Backs","year":"2006","journal-title":"Circ Res"},{"key":"2026010418524236200_ehaf524-B167","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fcvm.2020.00034","article-title":"Therapeutic targets for the treatment of cardiac fibrosis and cancer: focusing on TGF-\u03b2 signaling","volume":"7","author":"Parichatikanond","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"2026010418524236200_ehaf524-B168","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A Phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"2026010418524236200_ehaf524-B169","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/eurheartj\/ehaa791","article-title":"CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure","volume":"42","author":"Batkai","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010418524236200_ehaf524-B170","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/s41467-017-01737-4","article-title":"Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling","volume":"8","author":"Sassi","year":"2017","journal-title":"Nat Commun"},{"key":"2026010418524236200_ehaf524-B171","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/CIRCHEARTFAILURE.115.002225","article-title":"Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure","volume":"8","author":"Nevers","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026010418524236200_ehaf524-B172","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1093\/cvr\/cvac142","article-title":"Emerging epigenetic therapies of cardiac fibrosis and remodelling in heart failure: from basic mechanisms to early clinical development","volume":"118","author":"McKinsey","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026010418524236200_ehaf524-B173","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1161\/CIRCRESAHA.121.319737","article-title":"Cardiac resident macrophages prevent fibrosis and stimulate angiogenesis","volume":"129","author":"Revelo","year":"2021","journal-title":"Circ Res"},{"key":"2026010418524236200_ehaf524-B174","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.ajpath.2014.11.027","article-title":"Nonclassical resident macrophages are important determinants in the development of myocardial fibrosis","volume":"185","author":"Falkenham","year":"2015","journal-title":"Am J Pathol"},{"key":"2026010418524236200_ehaf524-B175","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nbt.1989","article-title":"Therapeutic siRNA silencing in inflammatory monocytes in mice","volume":"29","author":"Leuschner","year":"2011","journal-title":"Nat Biotechnol"},{"key":"2026010418524236200_ehaf524-B176","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/CAD.0b013e32833a4352","article-title":"Epigenetic tools in potential anticancer therapy","volume":"21","author":"Sebova","year":"2010","journal-title":"Anticancer Drugs"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehaf524\/64195028\/ehaf524.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehaf524\/64195028\/ehaf524.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T23:52:48Z","timestamp":1767570768000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/1\/37\/8246134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":176,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,2]]},"published-print":{"date-parts":[[2026,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf524","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,1]]},"published":{"date-parts":[[2025,9,2]]}}}